A phase IIa trial to evaluate the hemodynamic benefit of INOpulse in pulmonary hypertension associated with Sarcoidosis (PH-Sarcoidosis)
Phase of Trial: Phase II
Latest Information Update: 13 Aug 2019
Price : $35 *
At a glance
- Drugs Nitric oxide (Primary)
- Indications Pulmonary hypertension
- Focus Therapeutic Use
- Sponsors Bellerophon Therapeutics
- 13 Aug 2019 Status changed from planning to recruiting, as reported in a Bellerophon Therapeutics media release.
- 19 Nov 2018 New trial record
- 07 Nov 2018 According to a Bellerophon Therapeutics media release, the company expects to initiate this trial by year-end 2018 with results expected in 2019.